After screening, we identified the compound, chromenopyrimidinone (CPO), which inhibited the activity of the AFP+/CD133+ cell population and the proliferation of AFP+/CD133− cells without damaging hepatocytes in mixed HCC cell populations (Figure 1A). This evidence concerns the gene PROM1 and hepatocellular carcinoma.